Policy & Markets After Closing Theravance, Zymeworks Puts Numbers on Its $929M Royalty Bet Zymeworks completes its $929 million acquisition of Theravance Biopharma, adding a 35% US profit share in revefenacin (Yupelri) and a 20% share of any future ampreloxetine deal to its royalty-driven … By Fernando PafumiOct 6, 20268 Comments
IHME: Global Health Funding Falls Another 5% in 2026 After Hitting Lowest Level Since 2012 Nov 16, 2026
You must be logged in to post a comment.